ABBV vs HD: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and The Home Depot, Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-07-13.
AbbVie Inc. · Healthcare
$261.07
+1.2% upside to fair value
Grade C
High Quality
VS
The Home Depot, Inc. · Consumer Cyclical
$343.30
+34.6% upside to fair value
Grade A
High Quality
QuantHub Verdict
HD has more upside to fair value
(+34.6%).
HD trades at a lower forward P/E
(24.3x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
HD |
| Current Price |
$261.07 |
$343.30 |
| Fair Value Estimate |
$264.30 |
$462.14 |
| Upside to Fair Value |
+1.2%
|
+34.6%
|
| Market Cap |
$461.3B |
$342.3B |
| Forward P/E |
128.0x
|
24.3x
|
| EV / EBITDA |
31.0x
|
16.5x
|
| Price / Sales |
7.3x
|
2.0x
|
| Price / FCF |
22.1x
|
23.9x
|
| Revenue Growth YoY |
+12.4%
|
+4.8%
|
| Gross Margin |
70.7%
|
33.1%
|
| Operating Margin |
27.6%
|
12.4%
|
| Return on Equity |
68.0%
|
113.3%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
4.52%
|
4.18%
|
| Analyst Consensus |
Strong Buy
|
Buy
|
Investment Thesis
AbbVie Inc. is a leading healthcare company specializing in drug manufacturing with a strong focus on immunology and aesthetics. The company is transitioning from its historical Humira dominance, which has faced loss of exclusivity, toward high-growth assets like Skyrizi and Rinvoq that are driving robust revenue growth of 12.4% in the most recent quarter. Despite strong revenue growth and a dura…
The Home Depot, Inc. operates as a leading home improvement retailer in the consumer cyclical sector, leveraging a strong brand and cost advantages to maintain a durable competitive moat. Despite a modest revenue growth of 4.8% and a decline in earnings by 4.2% in the most recent quarter, the company exhibits exceptional profitability metrics including a 113.3% return on equity and solid margins …
Accumulation Zones
| Metric |
ABBV |
HD |
| Zone Low |
$198.23 |
$346.61 |
| Zone High |
$224.66 |
$392.82 |
| In Buy Zone? |
No
|
Yes
|